Inventiva S.A. (EPA: IVA)
France
· Delayed Price · Currency is EUR 2.445
+0.015 (0.62%)
Nov 22, 2024, 5:35 PM CET
Inventiva Revenue
Inventiva had revenue of 2.73M EUR in the half year ending June 30, 2024, a decrease of -19.40%. This brings the company's revenue in the last twelve months to 19.28M, down -12.56% year-over-year. In the year 2023, Inventiva had annual revenue of 23.16M with 23.12% growth.
Revenue (ttm)
19.28M
Revenue Growth
-12.56%
P/S Ratio
6.38
Revenue / Employee
156.71K
Employees
123
Market Cap
212.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 23.16M | 4.35M | 23.12% |
| Dec 31, 2022 | 18.81M | 10.31M | 121.32% |
| Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
| Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
| Dec 31, 2019 | 11.29M | 3.91M | 53.02% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 48.45B |
| EssilorLuxottica Société anonyme | 25.83B |
| Sartorius Stedim Biotech S.A. | 2.74B |
| bioMérieux S.A. | 3.81B |
| Eurofins Scientific SE | 6.72B |
| Ipsen S.A. | 3.44B |
| Virbac SA | 1.34B |
| Ramsay Générale de Santé SA | 5.01B |
Inventiva News
- 2 days ago - Inventiva reports 2024 Third Quarter Financial Information¹ - GlobeNewsWire
- 3 days ago - Combined General Meeting of December 11, 2024 - Availability of the preparatory documents - GlobeNewsWire
- 5 days ago - Alight to Enhance the Employee Experience with Launch of Alight Worklife® on Microsoft Teams - Business Wire
- 8 days ago - Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session - GlobeNewsWire
- 24 days ago - Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH - GlobeNewsWire
- 4 weeks ago - Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024 - GlobeNewsWire
- 5 weeks ago - Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants - GlobeNewsWire
- 5 weeks ago - Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday? - Benzinga